- |||||||||| Clinical, Review, Journal: Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. (Pubmed Central) - Sep 21, 2020
Due to the absence of or limitations in the data, no comments for clinicians can be provided on the pharmacokinetic DDIs for clonidine, centanafadine, mazindol, molindone, AR-08, P. tenuifolia extract and the French maritime pine bark extracts...A summary table for clinicians provides our current recommendations on pharmacokinetic DDIs of ADHD agents based on our literature review and the package inserts; whenever it was possible, we provide information on serum concentrations and dose correction factors. There will be a need to periodically update these recommendations and these correction factors as new knowledge becomes available.
- |||||||||| AR08 / Azurity Pharma
Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS) (clinicaltrials.gov) - Feb 12, 2015
P2, N=32, Terminated,
There will be a need to periodically update these recommendations and these correction factors as new knowledge becomes available. N=140 --> 32 | Suspended --> Terminated | Trial primary completion date: Oct 2014 --> May 2014; Study stopping criteria met with regards to vital sign measurements post dose.
- |||||||||| AR08 / Azurity Pharma
Enrollment closed: AR08 for Treatment of ADHD in Children (clinicaltrials.gov) - Aug 19, 2014
P2, N=120, Active, not recruiting,
N=140 --> 32 | Suspended --> Terminated | Trial primary completion date: Oct 2014 --> May 2014; Study stopping criteria met with regards to vital sign measurements post dose. Recruiting --> Active, not recruiting
- |||||||||| AR08 / Azurity Pharma
Enrollment open: AR08 for Treatment of ADHD in Children (clinicaltrials.gov) - Apr 1, 2014
P2, N=120, Recruiting,
Recruiting --> Suspended Active, not recruiting --> Recruiting
|
